CV vs LUCD
CV: CapsoVision commercializes AI-powered capsule endoscopy systems with panoramic imaging for small bowel and emerging colon diagnostics, targeting gastroenterologists globally. LUCD: Lucid Diagnostics develops EsoGuard, the first noninvasive DNA test for early detection of esophageal cancer precursors in millions of chronic GERD patients at risk.
Side-by-side fundamentals
| Metric | CV | LUCD | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $6.61 | $0.903 | |
| Market cap as of 2026-08-01 | $335M | $183M | |
| Net margin as of 2026-08-01 | -198.9% | -876.7% | CV higher |
| Gross margin as of 2026-08-01 | +51.7% | -31.4% | CV higher |
| Operating margin as of 2026-08-01 | -200.7% | -980.6% | CV higher |
| ROE as of 2026-08-01 | -184.2% | -370.2% | CV higher |
| ROA as of 2026-08-01 | -136.0% | -108.2% | LUCD higher |
| Debt / equity as of 2026-08-01 | 0.00 | 6.30 | CV lower |
| Revenue growth (YoY) as of 2026-08-01 | +0.3% | +23.0% | LUCD higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +105.6% | |
| Beta as of 2026-08-01 | -1.69 | 1.15 | |
| 1-year return as of 2026-07-27 close | +65.3% | -18.6% | CV higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.